A Randomized Phase 2 Clinical Trial Evaluating Sintilimab and Chidamide in Combination With or Without IBI305 in Patients With Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Latest Information Update: 13 May 2024
At a glance
- Drugs Bevacizumab (Primary) ; Sintilimab (Primary) ; Tucidinostat (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms CAPability-01
- 01 Apr 2024 Primary endpoint (The progression-free survival (PFS) rates at 18 weeks) has been met, according to the results published in the Nature Medicine.
- 01 Apr 2024 Results published in the Nature Medicine
- 24 Oct 2023 Results reporting efficacy and safety data presented at the 48th European Society for Medical Oncology Congress